Get the Stockscreener App
0.9583
0.35%
0.0033
After Hours:
.95
-0.0083
-0.87%
Ocugen Inc stock is traded at $0.9583, with a volume of 2.10M.
It is up +0.35% in the last 24 hours and up +0.14% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$0.955
Open:
$0.952
24h Volume:
2.10M
Relative Volume:
0.39
Market Cap:
$279.85M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-3.5493
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
-10.44%
1M Performance:
+0.14%
6M Performance:
+32.23%
1Y Performance:
-26.00%
1-Day Range:
$0.931
$0.9702
1-Week Range:
$0.931
$1.065
52-Week Range:
$0.515
$1.40
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.9583 | 279.04M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.65 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.13 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
428.14 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.15 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
298.52 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen Highlights Gene Therapy Advances, Strategic Deals in Second Quarter Update - MSN
AAV for the Hereditary Retinal Diseases Clinical Trial Pipeline Analysis Demonstrates 70+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Ocugen Reports Progress in Gene Therapy Trials - TipRanks
Ocugen Releases Second Quarter 2025 Financial Results, Provides Business Update - VisionMonday.com
Ocugen Analyst Ratings: Bullish and Bearish Perspectives Amidst Price Target Changes - AInvest
Ocugen Reaffirms Buy Rating and $7.00 Price Target with Chardan Capital - AInvest
Ocugen, Inc. SEC 10-Q Report - TradingView
Can Ocugen Inc. Rally Enough to Break EvenSector Based Breakout Stock Forecast Issued - metal.it
How volatile is Ocugen Inc. stock compared to the marketExplosive wealth accumulation - Jammu Links News
What are the latest earnings results for Ocugen Inc.Accelerated financial growth - Jammu Links News
What makes Ocugen Inc. stock price move sharplyExceptional market positioning - Jammu Links News
Is Ocugen Inc. stock overvalued or undervaluedMaximize your gains with professional insights - Jammu Links News
What are analysts’ price targets for Ocugen Inc. in the next 12 monthsGet real-time alerts on high-potential stocks - Jammu Links News
Should I hold or sell Ocugen Inc. stock in 2025Build a diversified portfolio for risk management - Jammu Links News
What institutional investors are buying Ocugen Inc. stockFree Stock Market Real-Time Monitoring - Jammu Links News
Ocugen Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
What are the technical indicators suggesting about Ocugen Inc.Free Stock Market Mentorship - Jammu Links News
Is it the right time to buy Ocugen Inc. stockSuperior returns - Jammu Links News
What are Ocugen Inc. company’s key revenue driversGet alerts on the hottest stocks daily - Jammu Links News
What catalysts could drive Ocugen Inc. stock higher in 2025Unstoppable trading performance - Jammu Links News
What markets is GWH.WS expanding into Is Ocugen Inc. stock a good long term investment option - Jammu Links News
Ocugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three Years - MSN
Ocugen outlines three licensing applications and 2026 commercialization plans while advancing gene therapy trials - MSN
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates - MSN
Evaluating Ocugen's Q2 Earnings and Strategic Progress: Clinical Milestones and Capital Efficiency as Catalysts for Long-Term Value Creation in Biotech Investing - AInvest
Ocugen Advances Gene Therapy for Blindness with Strategic Deals and Clinical Progress - AInvest
Ocugen Secures Licensing Deal for OCU400 in Korea, Enhancing Business Presence and Shareholder Value - AInvest
Ocugen, Inc. (OCGN): A High-Risk, High-Reward Biotech Play in Gene Therapy - AInvest
Ocugen, Inc. (NASDAQ:OCGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Ocugen Inc (OCGN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Ocugen Inc’s Earnings Call: Progress Amid Financial Challenges - MSN
Ocugen: Q2 Earnings Snapshot - Chron
Ocugen Provides Business Update with Second Quarter 2025 Financial Results - ADVFN Brasil
Ocugen's Strategic Path to 2026 BLA Filings and Global Gene Therapy Leadership - AInvest
Ocugen's Q2 2025 Earnings Call: Unpacking Contradictions in Trial Timelines, Manufacturing, and Strategic Direction - AInvest
Is Ocugen Inc. a growth stock or a value stockFree Stock Growth Plan For Smart Trading - Jammu Links News
Ocugen shares fall 5.83% intraday after mixed Q2 2025 earnings call and business update. - AInvest
Ocugen’s Revenue Surprised And Analysts Still See Room To Grow - Finimize
Ocugen Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Ocugen Q2 2025 sees narrow EPS beat, stock steady - Investing.com
Ocugen Provides Business Update with Second Quarter 2025 Financi - GuruFocus
Ocugen Provides Business Update with Second Quarter 2025 Financial Results | OCGN Stock News - GuruFocus
Ocugen: A High-Potential Biotech Play with Near-Term Catalysts and a Path to Profitability - AInvest
Press Release: Ocugen Provides Business Update With Second Quarter 2025 Financial Results - 富途牛牛
What is Ocugen Inc. company’s growth strategyAI Powered Tips With High Returns - jammulinksnews.com
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):